TipRanks

Notifications

Analysts Are Bullish on Top Healthcare Stocks: Sierra Oncology (SRRA), G1 Therapeutics (GTHX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sierra Oncology (SRRAResearch Report), G1 Therapeutics (GTHXResearch Report) and Rubius Therapeutics (RUBYResearch Report) with bullish sentiments.

Sierra Oncology (SRRA)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Sierra Oncology, with a price target of $35.00. The company’s shares closed last Thursday at $22.29, close to its 52-week high of $24.00.

According to TipRanks.com, Pantginis ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.3% and a 28.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.

Sierra Oncology has an analyst consensus of Strong Buy, with a price target consensus of $39.67.

See Insiders’ Hot Stocks on TipRanks >>

G1 Therapeutics (GTHX)

In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on G1 Therapeutics, with a price target of $71.00. The company’s shares closed last Thursday at $10.16, close to its 52-week low of $9.75.

According to TipRanks.com, White is a 4-star analyst with an average return of 6.8% and a 34.6% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for G1 Therapeutics with a $38.83 average price target, a 261.2% upside from current levels. In a report released yesterday, Needham also maintained a Buy rating on the stock with a $44.00 price target.

Rubius Therapeutics (RUBY)

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Rubius Therapeutics today and set a price target of $40.00. The company’s shares closed last Thursday at $12.60.

According to TipRanks.com, Fein is a 4-star analyst with an average return of 6.0% and a 40.6% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Deciphera Pharmaceuticals, and Global Blood Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for Rubius Therapeutics with a $20.67 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SRRA:

Tags: